HB-202

Phase 2Small molecule

UUniversity of Chicago

HB-202 is one of 4 small molecule programs targeting Head and Neck Cancers. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck CancersNot yet recruiting

Head and Neck CancersPhase 2

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Head and Neck Cancers

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

Taxol

Teva

Phase 2

2 3

Paraplatin

AAvyxa

Phase 2

2 4

HB-202

UUniversity of Chicago

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Not yet recruiting

Head and Neck Cancers

NCT05108870

Clinical

Trials by Indication[1]

Head and Neck Cancers1 trial

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

Not yet recruiting·UUniversity of Chicago·Phase 1/2·NCT05108870·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HB-202. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HB-202 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HB-202. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Chicago

HB-202

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Head and Neck Cancers1 trial

References

Drug Info

Quick Facts

Related News